Syndax Pharmaceuticals Inc’s recently made public that its Chief Financial Officer Goldan Keith A. unloaded Company’s shares for reported $58559.0 on Feb 10 ’25. In the deal valued at $15.50 per share,3,777 shares were sold. As a result of this transaction, Goldan Keith A. now holds 90,746 shares worth roughly $1.49 million.
Then, Metzger Michael A sold 13,288 shares, generating $206,017 in total proceeds. Upon selling the shares at $15.50, the Chief Executive Officer now owns 300,121 shares.
Before that, Gallagher Neil sold 4,618 shares. Syndax Pharmaceuticals Inc shares valued at $71,597 were divested by the President, Head of R&D at a price of $15.50 per share. As a result of the transaction, Gallagher Neil now holds 85,095 shares, worth roughly $1.39 million.
UBS initiated its Syndax Pharmaceuticals Inc [SNDX] rating to a Buy in a research note published on October 24, 2024; the price target was $37. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Scotiabank also remained covering SNDX and has decreased its forecast on January 31, 2024 with a “Sector perform” recommendation from previously “Sector outperform” rating. Mizuho started covering the stock on December 22, 2023. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Friday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock jump 2.44% to $16.38. Over the last five days, the stock has gained 8.62%. Syndax Pharmaceuticals Inc shares have risen nearly 23.90% since the year began. Nevertheless, the stocks have fallen -28.38% over the past one year. While a 52-week high of $25.34 was reached on 02/21/25, a 52-week low of $12.06 was recorded on 01/14/25. SMA at 50 days reached $14.05, while 200 days put it at $18.38.
Levels Of Support And Resistance For SNDX Stock
The 24-hour chart illustrates a support level at 16.02, which if violated will result in even more drops to 15.66. On the upside, there is a resistance level at 16.84. A further resistance level may holdings at 17.31. The Relative Strength Index (RSI) on the 14-day chart is 68.26, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.60, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 17.07%. Stochastics %K at 67.15% indicates the stock is a holding.
The most recent change occurred on October 25, 2023 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $29 price target.
